Dimeric glycoprotein VIFc

N/A

Report date: 2024/09/23 20:00:34

Base Information

Drug NameDimeric glycoprotein VIFc
Drug Alias NameDimeric glycoprotein VI-Fc二聚体糖蛋白VIFCRevaceptGPVI-FcPR-15
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlatelet membrane glycoprotein VI inhibitors
TargetsPlatelet membrane glycoprotein VI
Therapy Area/IndicationsThrombosisAtherosclerosisMyocardial Infarction +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCorimmun Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdvancecor Gmbh
Active IndicationsN/A
Inactive IndicationsThrombosisAtherosclerosisMyocardial Infarction +[8] 

Other Information

ATC CodeN/A
Related LinksN/A